Opinion

Video

Future Directions and Unmet Needs in Relapsed/Refractory MCL

Author(s):

Grzegorz S. Nowakowski, MD,Jennifer Crombie, MD

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Related Videos
Peter Forsyth, MD
Minoo Battiwalla, MD, MS
Leo I. Gordon, MD
Richard Kim, MD, Moffitt Cancer Center
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Tiago Biachi, MD, PhD
Related Content
BTK Inhibitors in Late-Relapse Mantle Cell Lymphoma | Image Credit: © Dr_Microbe - stock.adobe.com
November 19th 2024

Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Bendamustine/Obinutuzumab Induction in MCL
November 18th 2024

Bendamustine/Obinutuzumab Induction Generates Responses and MRD Negativity in Treatment-Naive MCL

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Tanios S. Bekaii-Saab, MD
November 17th 2024

Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation